Morepen Laboratories has successfully transitioned its Rs 825 crore CDMO mandate from validation and qualification stage to commercial execution. According to the company's latest press release, the company has completed its first commercial dispatch valued at approximately Rs 50 crore during Q1FY2026-27. This milestone marks the successful commencement of commercial supplies under the substantial contract, with the company now focusing on scaling up operations and expanding capacity to pursue additional customer and product opportunities within the CDMO segment. The commercial rollout is significant as it converts a previously announced order into revenue-generating execution, with investors now closely watching the pace of quarterly dispatches and capacity expansion as indicators of how quickly the company can scale the programme.
Following the completion of the first batch, Morepen expects to scale the program further in the coming quarter with additional supplies of approximately Rs 225 crore expected during Q2FY2026-27, subject to customer schedules and regulatory/commercial requirements. As reported by the company's press release, this represents a significant revenue ramp-up from the initial Rs 50 crore dispatch, with the company projecting a 50% revenue increase in Q2FY2026-27 driven by the additional supplies under the same mandate. Managing Director Sanjay Suri stated that the commencement of commercial supplies validates the company's investment in manufacturing infrastructure and supply chain readiness, with the focus now shifting to scaling up operations and strengthening the CDMO platform to serve additional customers and products.
The company is actively strengthening its manufacturing infrastructure to support larger CDMO opportunities. According to the latest updates, total reactor capacity is expected to reach approximately 600 KL by the end of Q2, followed by further expansion toward 800 KL and 1,000 KL in subsequent phases. This expansion strategy positions Morepen for increased capacity to handle growing CDMO requirements and supports the company's objective to deepen customer partnerships and participate in long-duration global manufacturing opportunities across APIs, finished formulations, diagnostics, and consumer healthcare. The company continues to invest in manufacturing infrastructure, regulatory capabilities and research to strengthen its position in the global pharmaceutical supply chain.
The announcement kept Morepen Laboratories share price in focus during Wednesday's trading session, with shares trading at ₹61.39, up 3.84% as of 9:28 AM IST on July 1, 2026. As per HDFC SKY, investors reacted positively to the start of commercial execution under the large manufacturing mandate, with the market closely tracking delivery schedules, capacity ramp-up and revenue contribution from the mandate in the coming quarters. The pharmaceutical and healthcare company, which operates across active pharmaceutical ingredients (APIs), finished formulations, diagnostics and consumer healthcare products, continues to expand its CDMO operations to serve domestic and international pharmaceutical customers alongside its branded healthcare business.
